Arcturus Therapeutics Holdings Inc. - 8-K Filing

Arcturus Therapeutics reports Q3 2026 revenue of $18.3M driven by CSL Seqirus termination payment; maintains cash runway through year-end 2028. (Items: 2.02 Results of Operations and Financial Conditions, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ARCT

Read the full article at SEC EDGAR

More Regulatory news